ArticlePloS one2023
The prevalence and treatment rate trends of osteoporosis in postmenopausal women.
Article in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 33 citations in OpenAlex.
- The association between body mass index and osteoporosis, with consideration of sex differences: a systematic review and dose-response meta-analysis.BMC musculoskeletal disorders · 2026Pooled it
- Efficacy and safety of denosumab biosimilars in the treatment of postmenopausal osteoporosis: A systematic review of randomized clinical trials.Clinical and experimental medicine · 2026Pooled it
- Shoulder arthroplasty in the osteoporotic patient: do bisphosphonates make a difference?JSES international · 2026Article
- Advancing osteoporosis opportunistic screening: multicenter validation of a deep learning algorithm using abdominal CT scans.Abdominal radiology (New York) · 2026Article
- MRI-Based Vertebral Bone Quality Scoring for Opportunistic Osteoporosis Screening in Postmenopausal Women: A QCT-Referenced Study.Calcified tissue international · 2026Article
- Low forearm bone density as a clue to suspect primary hyperparathyroidism in postmenopausal women with osteoporosis: a retrospective study.Archives of osteoporosis · 2026Article
- Yishen Gushu formula exerts osteoprotective effects in OVX-Induced PMOP rats: role of ferroptosis Inhibition and iron metabolism correction.Hereditas · 2026Article
- Branched‑chain amino acid metabolism and bone metabolism: Implications for osteoporosis pathogenesis and therapeutic strategies (Review).International journal of molecular medicine · 2026Review
- Integrating Single-Cell and Microarray Data to Explore the Role of Autophagy-Related Gene Atg7 in Osteoporosis.Journal of inflammation research · 2026Article
- Pectoral muscle cross-sectional area correlates with bone mineral density in postmenopausal women.Frontiers in medicine · 2026Article
- Value of serum uric acid in a risk prediction model for postmenopausal osteoporosis.Archives of gynecology and obstetrics · 2025Article
- Multiple large language models versus clinical guidelines for postmenopausal osteoporosis: a comparative study of ChatGPT-3.5, ChatGPT-4.0, ChatGPT-4o, Google Gemini, Google Gemini Advanced, and Microsoft Copilot.Archives of osteoporosis · 2025Article
- Correlation of serum pentraxin 3 expression with disease severity and its prognostic value in postmenopausal osteoporosis.BMC musculoskeletal disorders · 2025Article
- Time Is Bone: Missed Opportunities for Secondary Prevention After a Hip Fracture.Journal of clinical medicine · 2025Review
- Association of reproductive characteristics with osteoporosis and FRAX scores in Chinese postmenopausal women: a QCT-based cross-sectional study.Scientific reports · 2025Article
- Short-Term Administration of Parathyroid Hormone Improves Wound Healing Around Implants in an Osteoporotic Rat Model.Journal of clinical medicine · 2025Article
- Comparative analysis of ChatGPT-4o mini, ChatGPT-4o and Gemini Advanced in the treatment of postmenopausal osteoporosis.BMC musculoskeletal disorders · 2025Article
- Cutaneous Changes Beyond Psoriasis: The Impact of Biologic Therapies on Angiomas and Solar Lentigines.Medicina (Kaunas, Lithuania) · 2025Observational
- Ovarian Aging: The Silent Catalyst of Age-Related Disorders in Female Body.Aging and disease · 2025Review
- Identifying Herbal Candidates and Active Ingredients Against Postmenopausal Osteoporosis Using Biased Random Walk on a Multiscale Network.International journal of molecular sciences · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo evaluate the prevalence and treatment of postmenopausal women with osteoporosis in recent years, analyze differences between the prevalence diagnosed by physicians and the prevalence detected by bone mineral density (BMD), and observe the trends of prevalence and treatment rate of osteoporosis in postmenopausal women over time are of great value for the management of osteoporosis.
methodsThis cross-sectional study collected the data of 4012 postmenopausal women from the National Health and Nutrition Examination Survey (NHANES) from 2005 to 2010, 2013 to 2014 and 2017 to 2018. The prevalence of osteoporosis and osteopenia as well as the treatment rate of osteoporosis were analyzed using Mann-Kendall trend test. Subgroup analysis was conducted in different age, race, body mass index (BMI), diabetes, hypertension, or glucocorticoid use groups.
resultsThe overall prevalence of physician diagnosed of osteoporosis was 17.4% and was fluctuated in a small range and remained relatively stable within a certain range (Mann-Kendall trend test: Z = 2.20, P = 0.027) during 2005-2018. The prevalence of osteoporosis in postmenopausal women determined by bone mineral density (BMD) examination reached 9.2% during the five cycles. From 2005 to 2018, the prevalence of physician diagnosed osteoporosis fluctuated in a small range. For osteopenia measured by BMD, the prevalence was 59.6% and a gradual increasing trend was found between 2005 and 2018 (Mann-Kendall trend test: Z = 2.20, P = 0.027). Among patients with physician diagnosed osteoporosis, the treatment rate reached 70.49%. The treatment rate of physician diagnosed osteoporosis was decreased from 2005 to 2008, and further decreased from 2009 to 2018 (Mann-Kendall trend test: Z = -2.20, P = 0.027). The actual treatment rate of osteoporosis patients was 55.53%. During 2005-2018, the actual treatment rate of osteoporosis showed a continuous decline (Mann-Kendall trend test: Z = -2.20, P = 0.027).
conclusionOsteoporosis management might be insufficient and more efforts are needed to improve the diagnosis and treatment rates of osteoporosis in postmenopausal women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.